**TITLE:** Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab

**RUNNING TITLE:** Effect of alemtuzumab on MTR gradients

**AUTHORS:** J. William L. Brown MRCP*, 1,2 Ferran Prados Carrasco PhD*, 1,3,4 Arman Eshaghi MD, 1,5 Carole H. Sudre PhD, 6,7 Tom Button PhD MRCP, 8 Matteo Pardini MD PhD, 1,9 Rebecca S. Samson PhD, 1 Sebastien Ourselin PhD, 6 Claudia A.M. Gandini Wheeler-Kingshott PhD, 1,10,11 Joanne L Jones PhD FRCP, 2 Alasdair J Coles PhD FRCP, 2 Declan T. Chard PhD FRCP 1,12

* These authors contributed equally to this work

**AFFILIATIONS:**

1. NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
2. Department of Clinical Neurosciences, University of Cambridge, Box 165, Cambridge Biomedical Campus, Cambridge
3. Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, United Kingdom
4. eHealth Center, Universitat Oberta de Catalunya, Barcelona, Spain
5. Centre for Medical Image Computing (CMIC), Department of Computer Science, University College London, London, United Kingdom
6. School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
7. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
8. Neurology Department, York Hospital, York, UK.
9. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, and IRCCS AOU San Martino-IST, Genoa, Italy
10. Brain MRI 3T Research Centre, IRCCS Mondino Foundation, Pavia, Italy.
11. Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy
12. National Institute for Health Research (NIHR) University College London Hospitals
(UCLH) Biomedical Research Centre, UK.
ABSTRACT

Background

In relapse-onset multiple sclerosis (MS), tissue abnormality – as assessed with magnetisation transfer ratio (MTR) imaging - is greater in the outer cortical and inner periventricular layers. The cause of this remains unknown but meningeal inflammation has been implicated, particularly lymphoid follicles, which are seen in secondary progressive (SP) but not primary progressive (PP) MS. Cortical and periventricular MTR gradients might therefore differ in PPMS and SPMS if these follicles are responsible.

Objective

We assessed cortical and periventricular MTR gradients in PPMS; and compared gradients between people with PPMS and SPMS.

Methods

Using an optimised processing pipeline, periventricular normal-appearing white matter and cortical grey-matter MTR gradients were compared between 51 healthy controls and 63 people with progressive MS (28 PPMS, 35 SPMS).

Results

The periventricular gradient was significantly shallower in healthy controls (0.122 percentage units (pu)/band) compared to PPMS (0.952 pu/band, \( p<0.0001 \)) and SPMS (1.360 pu/band, \( p<0.0001 \)). The cortical gradient was also significantly shallower in healthy controls (-2.860 pu/band) compared to PPMS (-3.214 pu/band, \( p=0.038 \)) and SPMS (-3.328 pu/band, \( p=0.016 \)).
Conclusion

Abnormal periventricular and cortical MTR gradients occur in both PPMS and SPMS suggesting comparable underlying pathological processes.
INTRODUCTION

There is ongoing debate as to whether or not primary progressive (PP) and secondary progressive (SP) multiple sclerosis (MS) are essentially the same disease, barring the preceding relapsing-remitting (RR) phase: the age at onset and rate of progression are similar\(^1\) and lesion morphology in relapse-onset and PPMS are identical,\(^2\) but differences have been observed in both MRI and histopathological studies.\(^3, 4\) Post-mortem studies have recently revealed meningeal inflammation in all types of MS,\(^5-7\) although the most structured form - lymphoid follicle-like aggregates - have only been observed in SPMS, not in PPMS.\(^6\) The presence of these follicles - noted in about 40% of people with SPMS - is associated with more rapid clinical progression, and histopathologically with subpial demyelination and a gradient of cortical axonal loss.\(^8\) This raises seemingly conflicting possibilities that either lymphoid follicles are themselves not relevant to progression, or that the mechanisms leading to progression differ significantly between PPMS and SPMS.

Consistent with these histopathological findings, tissue abnormality, as assessed by magnetisation transfer ratio (MTR) \textit{in vivo}, increases towards the cortical surfaces in all clinical stages of relapse-onset MS.\(^9\) We have recently shown similar gradients in MTR abnormality around the ventricles in relapse-onset MS.\(^10\) Both cortical and periventricular gradients are evident soon after a clinically-isolated syndrome\(^11, 12\) and are more marked in SPMS compared to RRMS.\(^9, 10\) The processes underlying abnormal cortical and periventricular MTR gradients remain unknown, but one possibility is that they are both linked with meningeal inflammation, perhaps through a CSF-mediated factor.\(^8\) We previously reported the absence of a statistically significant cortical MTR gradient in PPMS\(^9\).
but did not investigate periventricular gradients. If a common factor links cortical and periventricular MTR gradients, we would expect the latter to also be absent in PPMS.

Using our recently optimised pipeline for MTR gradient analysis\cite{13} we aimed to: (i) confirm the absence of a gradient of cortical MTR abnormality in PPMS; (ii) determine if an abnormal periventricular MTR gradient is seen in PPMS; (iii) compare gradients and their evolution between people with PPMS and SPMS; and (iv) explore correlations with disability. As the processing pipeline has been optimised since previous publications\cite{9,10} we also reprocessed data from people with RRMS and present them as an online supplement (Supplementary Tables 1-2).
MATERIALS AND METHODS

Subjects
From an observational cohort we analysed data from healthy controls and people with PPMS, SPMS or RRMS (as defined by the Lublin-Reingold criteria) that had undergone MRI scanning with a protocol including the acquisition of volumetric T1-weighted images and MTR data. Some had repeat imaging performed 1-4 years later. All people in the MS groups additionally required an Expanded Disability Status Scale (EDSS) score at baseline. The study was approved by our local institutional ethics committee and written informed consent was provided by each participant.

MRI
Imaging was performed on a 3T Philips Achieva system (Philips Healthcare, Best, The Netherlands), and included: (i) Dual-echo proton density / T2 weighted scans (1x1x3 mm³, TR = 3500 ms, TE = 19/85 ms) for lesion identification; (ii) T1-weighted scans (3D inversion-prepared (T1=824 ms) fast field echo sequence (TR/TE = 6.9/3.1 ms, flip angle = 8°) for volumetric measures and segmentation; and (iii) MTR data using a 3D-slab-selective fast field echo sequence with two echoes (TR = 6.4 ms, TE1/TE2 = 2.7/4.3 ms, flip angle = 9° with and without sinc-Gaussian shaped MT pulses of nominal flip angle 360°, offset frequency 1 kHz, duration 16 ms). All images were acquired sagittally with a field-of-view of 256x256x180mm³ across the whole brain.

Image analysis
White matter (WM) lesions were outlined on PD/T2-weighted images using the semi-automated tool 3D-slicer and checked by DTC. The resultant lesion masks were affine co-
registered to the T1-weighted images via pseudo-T1 images (as previously described\textsuperscript{17}) and transformed to T1-space using nearest-neighbour interpolation to enable lesion-filling of the T1-weighted images.\textsuperscript{18} The MTon and MToff images were then registered to the T1-weighted volume using NiftyReg,\textsuperscript{19} and MTR maps (in percentage units (pu)), were calculated as follows: $\frac{(\text{MToff} - \text{MTon})}{\text{MToff}} \times 100$. T1-weighted volumes were segmented into WM, grey matter (GM) and cerebrospinal fluid (CSF) using the geodesic information flows (GIF)\textsuperscript{20} algorithm. Lesions (plus a 2mm perilesional rim\textsuperscript{21}) were subtracted from each participant’s WM mask, generating a normal-appearing (NA) WM mask. The NAWM and cortical GM (CGM) volumes were used as covariates in the periventricular and cortical models respectively. Brain parenchymal fraction (BPF) was used as an alternative covariate in both periventricular and cortical gradient models in a sensitivity analysis to mirror a previous paper.\textsuperscript{13} It was calculated as follows: $(\text{GM volume} + \text{WM volume}) / (\text{GM volume} + \text{WM volume} + \text{CSF volume})$.

The NAWM mask was intersected with the MTR map, and segmented into 10 concentric bands using the normalised distance map derived from the normal to the Laplace equation isolines.\textsuperscript{13} This approach generates bands of varying thickness, but accounts for the differences in brain thickness within different brain regions plus the effects of atrophy: the relative position of a given band to the surface of the brain should therefore be maintained. Consistent with previous work using 3D MTR data, the innermost (periventricular) and outermost (pericortical) bands were excluded to mitigate partial volume effects.\textsuperscript{10} From the remaining 8 bands the periventricular NAWM gradient was calculated as follows: $((\text{mean NAWM MTR band 3} - \text{mean NAWM MTR band 1}) / 2)$. Consistent with previous work, the CGM was also segmented into two bands using the Laplace method\textsuperscript{9} but rather than using the absolute outer-band MTR value\textsuperscript{9} (which will be subject to inter-individual variations in
whole brain MTR22), the cortical gradient was instead calculated as: ((mean cortical GM MTR band 2 (outer) – mean cortical GM MTR band 1 (inner)) / 2). An alternative method for calculating the cortical gradient – applying the CGM mask to a 12-ring segmentation, removing the outermost band, then calculating the cortical gradient over the 3 outermost rings – requires a lower probabilistic segmentation threshold13 to achieve similarly-sized rings, so increasing the chances of partial volume with adjacent WM and CSF, affecting results, and it also does not account for cortical folding as well as the present method. The mean NAWM and cortical GM MTR were also calculated in each participant for use as covariates in sensitivity analyses. Finally, to explore whether differences between current and previous9 results reflected the greater number of people studied, we restricted the groups to the 19 people with PPMS and 35 healthy controls previously examined9 and repeated the analyses.

Statistics

MTR gradient values are presented as mean ± standard error, and all longitudinal differences were annualised to circumvent variable interscan intervals. We used general linear models to compare baseline gradients between groups and mixed-effects linear models to compare the rate of gradient change between disease subtypes. Consistent with previous work these models were adjusted for age and sex. Additionally, these models were also adjusted for either NAWM volume (periventricular gradient models) or cortical volume (cortical gradient models); and then repeated adjusting for brain parenchymal fraction (BPF) for comparison to previous work.13 To examine whether differences in gradients might be driven by more diffuse MTR changes we performed sensitivity analyses, additionally
adjusting all periventricular gradient models for mean NAWM MTR, and all cortical gradient models for mean CGM MTR.

Finally, we ran univariate general linear models comparing (i) baseline periventricular gradients with baseline cortical gradients; and (iii) baseline gradients with baseline disease duration, EDSS score and time from the last relapse. All analyses were performed in R (v3.3.1). Results were considered statistically significant at the $p < 0.05$ level.
RESULTS

Imaging was performed in 51 healthy controls (12 with follow-up imaging after median 2.1 (range 1.5 – 2.7) years), 28 people with PPMS (14 with follow-up imaging after median 2.3 (range 1.2 – 3.5) years) and 35 people with SPMS (15 with follow-up imaging after median 1.6 (range 1.1 – 2.4) years). The control group were younger than either progressive group (Table 1), and the SPMS group had a greater proportion of females than the PPMS and control groups (all models were adjusted for age, gender and either NAWM volume or CGM volume).

The MTR in each band was greater (less abnormal) in healthy controls compared to those with PPMS and SPMS (Figure 1). The NAWM periventricular gradient was significantly shallower (less abnormal) in healthy controls (0.122 ± 0.038 pu/band) compared to those with both PPMS (0.952 ± 0.185 pu/band, $p < 0.0001$) and SPMS (1.360 ± 0.143 pu/band, $p < 0.0001$), Table 2, Figure 2A. These differences persisted when the models were additionally adjusted for mean NAWM MTR ($p = 0.015$ and $p < 0.0001$ respectively) and when the models were adjusted for BPF instead of NAWM volume ($p < 0.001$ and $p = 0.003$ respectively). No significant differences in periventricular gradient were found between people with PPMS and SPMS ($p = 0.444$), including after adjustment for mean NAWM MTR ($p = 0.191$) or when covarying for BPF instead of NAWM volume ($p = 0.604$). The cortical gradient was significantly shallower (less abnormal) in healthy controls (-2.860 ± 0.051 pu/band) compared with both PPMS (-3.214 ± 0.103 pu/band, $p = 0.038$) and SPMS (-3.328 ± 0.101 pu/band, $p = 0.016$), Figure 2B. These differences lost significance when the models were additionally adjusted for mean cortical GM MTR ($p = 0.570$ and $p = 0.589$ respectively), and when the models covaried for BPF instead of cortical volume ($p = 0.575$ respectively).
and \( p = 0.530 \) respectively). When the MS and healthy control groups were limited to those analysed previously\(^9\) the results were consistent with those previously seen: a significant difference was seen between healthy controls and SPMS \( (p=0.030) \) but not PPMS \( (p = 0.150) \). No significant differences in cortical gradient were found between people with PPMS and SPMS \( (p = 0.372) \), including after adjustment for mean cortical MTR \( (p = 0.915) \). The baseline demographics and imaging outcomes (including model results) for people with RRMS are presented in Supplementary Tables 1 and 2 respectively.

When all people with MS were grouped (RRMS, SPMS, PPMS), the baseline periventricular gradient was associated with baseline EDSS score \((\beta \ 0.100, p=0.011)\) and disease duration \((\beta \ 0.023, p=0.005)\) but not time from last relapse \((\beta \ 0.021, p=0.357)\). These associations did not materially change when additionally adjusted for clinical classification (Table 3). The baseline cortical gradient was associated with baseline EDSS score \((\beta \ -0.082, p=0.001)\) and disease duration \((\beta \ -0.015, p=0.004)\) but not time from last relapse \((\beta \ -0.011, p=0.554)\). These associations did not materially change when additionally adjusted for clinical classification. Results for each disease subgroup are shown in Table 3. A significant association was found between the periventricular gradient and cortical gradient \((\beta \ -0.609, p<0.0001)\) which remained unchanged after additionally adjusting for disease group (Table 3).

In those with radiological follow-up (Tables 1-2), the annualised change in periventricular gradient was not significantly different between healthy controls \(-0.011 \pm 0.051 \text{ pu/band/year}\) and people with either PPMS \( (0.090 \pm 0.040 \text{ pu/band/year}, p = 0.951) \) or SPMS \( (0.021 \pm 0.030 \text{ pu/band/year}, p = 0.473) \). Including change in mean NAWM MTR in the
model did not materially alter the results ($p = 0.882$ and $p = 0.343$, respectively). Similarly, no change in the annualised rate of change in cortical gradient was seen between healthy controls ($0.090 \pm 0.146 \text{ pu/band/year}$) and people with either PPMS ($-0.018 \pm 0.039 \text{ pu/band/year}, p = 0.553$) or SPMS ($0.037 \pm 0.009 \text{ pu/band/year}, p = 0.913$). Including change in mean cortical GM MTR in the model did not materially alter the results ($p = 0.964$ and $p = 0.350$, respectively).
DISCUSSION

We identified both periventricular and cortical MTR gradients in PPMS and replicated our previous findings of cortical and periventricular gradients in SPMS. The cortical and periventricular gradients did not differ significantly between the PPMS and SPMS groups. In the few subjects with longitudinal imaging, when compared with healthy controls, no significant changes in these gradients were observed over a median period of 2 years. When all people with MS were combined, significant associations were seen between periventricular and cortical gradient severity; and both gradients increased with increasing disability and disease duration.

The present results suggest that the processes underlying cortical and periventricular MTR gradients may be similar in PPMS and SPMS. The finding of a cortical gradient in PPMS in the present study but not our previous work appears to reflect the larger cohort (28 versus 19 with PPMS; 51 versus 35 healthy controls). However, while the optimised processing pipeline better accounts for cortical folding, it’s ability to distinguish cortical gradients from whole cortical MTR effects is severely limited because cortical gradients are calculated from the only 2 cortical bands of MTR, which may explain why all cortical models lost significance when additionally covaried for mean CGM MTR.

The pathological substrate and pathogenic processes underlying these MTR gradients remain unknown, but MTR reductions are correlated with demyelination in the cortex and WM and additionally axonal loss in WM. In the cortex, demyelination and neuronal loss appear more extensive in the outer (subpial) layers so both might therefore contribute to a gradient in cortical MTR abnormality. Both have also been linked with meningeal
inflammation, particularly follicle-like lymphoid aggregates. The present findings suggest these follicles – reported in about 40% of people with SPMS but not in PPMS\(^6\) - are not necessary for a gradient in cortical MTR abnormality to occur. However, the absence of follicles in PPMS at post-mortem may reflect the relatively small number examined\(^6\) (n=7) and larger histopathological studies are warranted to confirm this. To the best of our knowledge no histopathological study has examined periventricular gradients, so it remains to be determined if the underlying substrates are similar to those in the cortex. However, the present results would be consistent with a common pathological process underlying them both.\(^{27,28}\)

The presence of a significant association between cortical and periventricular gradients in the RRMS group (n=56) but not the PPMS (n=28) or SPMS (n=35) groups may also reflect the smaller sample sizes, particularly given the significant association seen at the whole-group level when additionally covarying for clinical classification. The apparent absence of a change in gradients over time should also be interpreted with caution, given that only a small subset of the cohorts had serial MTR studies (12/51 healthy controls, 14/28 with PPMS and 15/35 with SPMS), and follow-up was limited to 1.6-2.3 years (Table 1). This and previous cross-sectional works have shown a steeper periventricular gradient in SPMS compared with RRMS.\(^{10}\) and we found significant associations between disease duration and gradient severity (Table 3), collectively suggesting that gradients do worsen over time. Associations of cortical and periventricular MTR gradients with disability, as measured by EDSS scores, were also modest. Only in SPMS did cortical MTR gradients correlate with EDSS scores, though the significant correlations at the whole-group level - even when covarying for clinical classification - may suggest that the lack of association in the RRMS and PPMS groups reflects the smaller numbers. Furthermore, spinal cord pathology was not assessed,
which may be of greater clinical relevance in PP than SPMS\textsuperscript{29}; and EDSS scores exceeding 3.5 essentially reflect impaired mobility and do not capture cognitive or memory impairments,\textsuperscript{30} both of which may be associated with cortical pathology.\textsuperscript{31} Further work using larger cohorts and spinal cord examination is needed to explore these issues.

**CONCLUSION**

As with SPMS, periventricular and cortical gradients are present in PPMS, and do not appear to differ substantially between these subtypes of progressive MS. Histopathological examination of the substrates underlying these gradients may provide useful insights into the processes leading to them.
ACKNOWLEDGEMENTS

The authors thank the people who took part in the study, the MS Society of Great Britain and Northern Ireland and the National Institute for Health Research University College London Hospitals Biomedical Research Centre for financial support.

FUNDING

The NMR research unit at the Queen Square Multiple Sclerosis centre is supported by the MS Society of Great Britain and Northern Ireland and the UCLH-UCL Biomedical Research Centre. J.W.L.B is in funded through a Next Generation Fellowship funded by the Grant Charity of the Freemason’s. FP is a non-clinical Guarantors of Brain fellow. CHS is supported by the Alzheimer’s Society. R.S.S. is funded by the MS society of the UK and INSPIRED (a spinal cord imaging study funded jointly by Spinal Research, Wings for Life and the Craig H Nielsen foundation). CGWK also receives funding from the Horizon2020 EU programme (H2020-EU.3.1 (634541)) and the UK MS Society.

DECLARATION OF CONFLICTING INTERESTS

William Brown reports travel expenses, speaker honoraria and consulting fees from Novartis, Biogen, and Sanofi Genzyme.
Azmain Chowdhury has nothing to report.
Baris Kamber has nothing to report.
Ferran Prados Carrasco has nothing to report.
Arman Eshaghi has nothing to report.
Carole Sudre has nothing to report.
Matteo Pardini reports research support from Novartis, speaker honoraria from Merk and Novartis and travel expenses for attending meetings from Merk, Novartis, Roche and Teva.
Rebecca Samson has nothing to report.
Steven van de Pavert has nothing to report.
Claudia Gandini Wheeler-Kingshott has nothing to report.

Declan Chard has, in the last three years, received honoraria (paid to his employer) from Excemed for faculty-led education work; had meeting expenses funded by Merck, MS Trust, National MS Society, Novartis, Société des Neurosciences, Swiss MS Society, ECTRIMS and EAN; and has previously held stock in GlaxoSmithKline. He has received research funding from the International Progressive MS Alliance, the MS Society of Great Britain and Northern Ireland, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre.
REFERENCES


Table 1: Participant baseline demographics

<table>
<thead>
<tr>
<th></th>
<th>Untreated</th>
<th>Alemtuzumab-treated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=15</td>
<td>All N=19</td>
</tr>
<tr>
<td>Mean age, years ± SD</td>
<td>37.5 ± 7</td>
<td>32.8 ± 9.5</td>
</tr>
<tr>
<td></td>
<td>29.9 ± 2.3</td>
<td>33.6 ± 7.7</td>
</tr>
<tr>
<td>Female : male</td>
<td>10 : 5</td>
<td>13 : 6</td>
</tr>
<tr>
<td></td>
<td>3 : 1</td>
<td>10 : 5</td>
</tr>
<tr>
<td>Mean disease duration, years ± SD</td>
<td>1.69 ± 0.72</td>
<td>1.59 ± 0.77</td>
</tr>
<tr>
<td></td>
<td>2.03 ± 1.19</td>
<td>1.48 ± 0.62</td>
</tr>
<tr>
<td>Mean annualised relapse rate ± SD</td>
<td>1.72 ± 1.03</td>
<td>2.73 ± 1.28</td>
</tr>
<tr>
<td></td>
<td>2.92 ± 1.01</td>
<td>2.68 ± 1.38</td>
</tr>
<tr>
<td>Median EDSS (range)</td>
<td>1 (0-4)</td>
<td>1.5 (0-3)</td>
</tr>
<tr>
<td></td>
<td>2.25 (0-2.5)</td>
<td>1.5 (0-3)</td>
</tr>
</tbody>
</table>

Table 1. Participant baseline demographics. SD=standard deviation. EDSS=Expanded Disability Status Scale; NA=not available.
<table>
<thead>
<tr>
<th></th>
<th>Untreated All N=15</th>
<th>Alemtuzumab-treated All N=19</th>
<th>p-value</th>
<th>Alemtuzumab-treated Relapse within 4y N=4</th>
<th>No relapse within 4y N=15</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTR gradient ± SE (u/µm/µm²/year)</td>
<td>0.504 ± 0.068</td>
<td>0.647 ± 0.062</td>
<td>0.044</td>
<td>0.871 ± 0.197</td>
<td>0.588 ± 0.057</td>
</tr>
<tr>
<td></td>
<td>0.030 ± 0.025</td>
<td>-0.045 ± 0.016</td>
<td>0.028</td>
<td>-0.116 ± 0.060</td>
<td>-0.026 ± 0.009</td>
</tr>
<tr>
<td>NAWM MTR ± SE (µm³/year)</td>
<td>33.518 ± 0.329</td>
<td>33.112 ± 0.339</td>
<td>0.211</td>
<td>32.590 ± 0.994</td>
<td>33.251 ± 0.332</td>
</tr>
<tr>
<td></td>
<td>-0.306 ± 0.119</td>
<td>0.279 ± 0.062</td>
<td><strong>0.008</strong></td>
<td>0.412 ± 0.227</td>
<td>0.244 ± 0.057</td>
</tr>
<tr>
<td>T2 lesion number ± SE (lesions/year)</td>
<td>16.400 ± 2.891</td>
<td>25.579 ± 3.465</td>
<td>0.056</td>
<td>23.000 ± 6.621</td>
<td>26.267 ± 4.119</td>
</tr>
<tr>
<td></td>
<td>0.867 ± 0.503</td>
<td>-0.632 ± 0.480</td>
<td><strong>0.010</strong></td>
<td>0.167 ± 0.319</td>
<td>-0.844 ± 0.572</td>
</tr>
<tr>
<td>T2 lesion number ± SE (lesions/year)</td>
<td>11.200 ± 2.154</td>
<td>21.158 ± 3.209</td>
<td><strong>0.011</strong></td>
<td>17.250 ± 6.183</td>
<td>22.200 ± 3.719</td>
</tr>
<tr>
<td></td>
<td>1.633 ± 0.557</td>
<td>-0.736 ± 0.499</td>
<td><strong>0.001</strong></td>
<td>-0.750 ± 1.250</td>
<td>-0.733 ± 0.573</td>
</tr>
<tr>
<td>Parenchymal fraction ± SE</td>
<td>0.713 ± 0.006</td>
<td>0.712 ± 0.003</td>
<td>0.453</td>
<td>0.715 ± 0.001</td>
<td>0.710 ± 0.006</td>
</tr>
<tr>
<td></td>
<td>-0.003 ± 0.000</td>
<td>-0.003 ± 0.000</td>
<td><strong>0.450</strong></td>
<td>-0.002 ± 0.000</td>
<td>-0.003 ± 0.000</td>
</tr>
</tbody>
</table>

Table 2: Imaging outcomes at baseline and annualised change during follow-up.

SD = standard deviation. SE = standard error.
Table 2. Imaging outcomes at baseline and annualised changes during follow-up. BPF=brain parenchymal fraction. DGM=deep grey matter. NAWM=normal appearing white matter. SE=standard error. Magnetisation transfer ratio (MTR) is expressed as percentage units (pu). P values computed from nested mixed-effects models adjusted for age, gender, prior relapse rate, brain parenchymal fraction, scanner upgrade status and repeated measures. Statistically significant figures are emboldened.
Supplementary Materials

Baseline predictive capabilities: those who relapsed versus those who did not (untreated group)

During clinical follow-up (5 years), 10/15 untreated patients relapsed (all within the first 3 years). No difference was found in the baseline periventricular MTR gradient between those who relapsed compared to those who did not (0.462 ± 0.084pu/band versus 0.590 ± 0.120pu/band respectively, \( p=0.551 \)), including after adjustment for baseline whole-brain lesion number (\( p=0.847 \)), baseline periventricular lesion number (\( p=0.607 \)) or baseline mean whole brain NAWM MTR (\( p=0.438 \)). While a significant difference was found in baseline whole-brain lesion number (14.6 ± 2.8 versus 20 ± 6.9 respectively, \( p=0.043 \)), and a trend was seen in baseline periventricular lesion number (10.2 ± 2.4 versus 13.2 ± 4.7 respectively, \( p=0.052 \)), no differences were found in baseline brain parenchymal fraction (0.713 ± 0.008 versus 0.712 ± 0.007 respectively, \( p=0.978 \)) or baseline mean whole brain NAWM MTR (37.183 ± 0.216pu versus 37.036 ± 0.275pu respectively, \( p=0.898 \)) between those that relapsed versus those who did not.

Evolution over time: those who relapsed versus those who did not (untreated group)

The rate of change in MTR gradient was significantly different between those who relapsed and those who did not (0.071 ± 0.026pu/band/year versus -0.052 ± 0.036pu/band/year respectively, \( p=0.001 \)), and remained significant when change in whole brain lesion number (\( p=0.006 \)), change in periventricular lesion number (\( p=0.005 \)) or change in whole brain NAWM MTR (\( p=0.003 \)) were added to the model. The rate of change in mean whole brain NAWM MTR was not significantly different between those who relapsed and those who did not (-0.185 ± 0.038pu/year versus -0.181 ± 0.053pu/year respectively, \( p=0.850 \)), nor were the rates of change in whole-brain lesion number (1 ± 0.7/year versus 0.7 ± 0.6/year respectively, \( p=0.415 \)), periventricular lesion number (1.8 ± 0.8/year versus 1.4 ± 0.8/year respectively, \( p=0.561 \)) nor brain parenchymal fraction (-0.002 ± 0.001/year versus -0.005 ± 0.001/year respectively, \( p=0.273 \)).